The promise of N-acetylcysteine in neuropsychiatry

Trends in Pharmacological Sciences

Volumn 34, Issue 3, 2013, Pages 167-177

  Berk, Michael ^a,b,c,d   Malhi, Gin S ^e,f   Gray, Laura J ^a   Dean, Olivia M ^a,b,d  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ORYGEN RESEARCH CENTRE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

addiction; Alzheimer's; anxiety; autism; bipolar disorder; cannabis; depression; glutamate; glutathione; mania; neurodegeneration; obsessive compulsive disorder; Parkinson's; psychosis; schizophrenia; trichotillomania

Indexed keywords

ACETYLCYSTEINE; DOPAMINE; GLUTAMIC ACID; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; NUTRACEUTICAL; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOLISM; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTISM; BIOCHEMISTRY; BIPOLAR DISORDER; CANNABIS ADDICTION; COCAINE DEPENDENCE; CYTOKINE PRODUCTION; DOPAMINERGIC TRANSMISSION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GLUTAMATERGIC NEUROTRANSMISSION; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; METHAMPHETAMINE DEPENDENCE; MOLECULAR DYNAMICS; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OXIDATIVE STRESS; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SKIN PICKING; TOBACCO DEPENDENCE; TRICHOTILLOMANIA;

ACETYLCYSTEINE; ANIMALS; HUMANS; MENTAL DISORDERS;

EID: 84874652458     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.01.001     Document Type: Review

References (121)

1. S. Dodd N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility Expert Opin. Biol. Ther. 8 2008 1955 1962
2. O.M. Dean Translating the rosetta stone of N-acetylcysteine Biol. Psychiatry 71 2012 935 936
3. O. Dean N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action J. Psychiatry Neurosci. 36 2011 78 86
4. M. Arakawa, and Y. Ito N-Acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology Cerebellum 6 2007 308 314 (Pubitemid 350179062)
5. K.S. Kau Blunted cysteine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking Neuroscience 155 2008 530 537
6. V.I. Lushchak Glutathione homeostasis and functions: potential targets for medical interventions J. Amino Acids 2012 2012 736837
7. M.F. Olive Glutamatergic medications for the treatment of drug and behavioral addictions Pharmacol. Biochem. Behav. 100 2012 801 810
8. J.T. Kantrowitz, and D.C. Javitt N-Methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull. 83 2010 108 121
9. M.M. Moran Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking J. Neurosci. 25 2005 6389 6393 (Pubitemid 40962534)
10. R. Sattler, and M. Tymianski Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death Mol. Neurobiol. 24 2001 107 129 (Pubitemid 34066681)
11. D.A. Baker The origin and neuronal function of in vivo nonsynaptic glutamate J. Neurosci. 22 2002 9134 9141 (Pubitemid 35379084)
12. D.A. Baker Contribution of cystine-glutamate antiporter to the psychotomimetic effects of phencyclidine Neuropsychopharmacology 33 2008 1760 1772 (Pubitemid 351684701)
13. D.A. Baker Neuroadaptations in cysteine-glutamate exchange underlie cocaine relapse Nat. Neurosci. 6 2003 743 749 (Pubitemid 36792890)
14. 2+ in cultured rat forebrain neurons Neurosci. Lett. 133 1991 11 14
15. S.W. Leslie Stimulation of N-methyl-d-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione Mol. Pharmacol. 41 1992 308 314
16. V. Varga Glutathione is an endogenous ligand of rat brain N-methyl-d-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors Neurochem. Res. 22 1997 1165 1171 (Pubitemid 27327944)
17. P. Steullet Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia Neuroscience 137 2006 807 819 (Pubitemid 43053945)
18. 3H]dopamine release by glutathione in mouse striatal slices Neurochem. Res. 32 2007 1357 1364 (Pubitemid 46988197)
19. E. Gere-Paszti, and J. Jakus The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography Biomed. Chromatogr. 23 2009 658 664
20. T.G. Hastings The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease J. Bioenerg. Biomembr. 41 2009 469 472
21. K. Hashimoto Protective effects of N-acetyl-l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine Neuropsychopharmacology 29 2004 2018 2023 (Pubitemid 39486553)
22. N. Kaushal AC927, a sigma receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells Mol. Pharmacol. 81 2012 299 308
23. J. Hirrlinger Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells J. Neurosci. Res. 69 2002 318 326 (Pubitemid 34809481)
24. M.E. Raichle, and D.A. Gusnard Appraising the brain's energy budget Proc. Natl. Acad. Sci. U.S.A. 99 2002 10237 10239
25. S. Herculano-Houzel Scaling of brain metabolism with a fixed energy budget per neuron: implications for neuronal activity, plasticity and evolution PLoS ONE 6 2011 e17514
26. M. Valko Free radicals and antioxidants in normal physiological functions and human disease Int. J. Biochem. Cell Biol. 39 2007 44 84 (Pubitemid 44566469)
27. S. Selek Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 487 491 (Pubitemid 351187832)
28. J.F. Wang Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia Bipolar Disord. 11 2009 523 529
29. M. Kunz Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia Prog. Neuropsychopharmacol. Biol Psychiatry 32 2008 1677 1681
30. N. Buttner DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia Schizophr. Res. 93 2007 33 41 (Pubitemid 46817926)
31. A.C. Andreazza DNA damage in bipolar disorder Psychiatry Res. 153 2007 27 32 (Pubitemid 47376945)
32. Y. Che Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness J. Psychiatry Neurosci. 35 2010 296 302
33. C. Konradi Molecular evidence for mitochondrial dysfunction in bipolar disorder Arch. Gen. Psychiatry 61 2004 300 308 (Pubitemid 38295832)
34. X. Sun Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder J. Psychiatry Neurosci. 31 2006 189 196 (Pubitemid 43954738)
35. A. Sequeira Mitochondrial mutations and polymorphisms in psychiatric disorders Front. Genet. 3 2012 103
36. R.E. Anglin The psychiatric manifestations of mitochondrial disorders: a case and review of the literature J. Clin. Psychiatry 73 2012 506 512
37. M.D. Altschule Blood glutathione and eosinophil levels and hospital adjustment scale in chronic schizophrenia Arch. Gen. Psychiatry 1 1959 358 365
38. I. Altuntas Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients Clin. Chem. Lab. Med. 38 2000 1277 1281 (Pubitemid 32094401)
39. J.M. Looney, and H.M. Childs The lactic acid and glutathione content of the blood of schizophrenic patients J. Clin. Invest. 13 1934 963 968
40. M.D. Altschule Blood glutathione level in mental disease before and after treatment AMA Arch. Neurol. Psychiatry 67 1952 64 68
41. M. Erkan Ozcan Antioxidant enzyme activities and oxidative stress in affective disorders Int. Clin. Psychopharmacol. 19 2004 89 95
42. M. Bilici Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments J. Affect. Disord. 64 2001 43 51 (Pubitemid 32268670)
43. A.C. Andreazza 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder J. Psychiatry Neurosci. 34 2009 263 271
44. M. Berk Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT J. Affect. Disord. 131 2011 207 213
45. S. Lavoie Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients Neuropsychopharmacology 33 2008 2187 2199 (Pubitemid 351992093)
46. J.W. Gawryluk Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders Int. J. Neuropsychopharmacol. 14 2011 123 130
47. A. Kulak Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder Behav. Brain Res. 226 2012 563 570
48. -/- knockout mice Neurotoxicol. Teratol. 34 2012 450 457
49. K.H. Choy Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats Eur. J. Pharmacol. 649 2010 224 228
50. O. Dean N-Acetyl cysteine inhibits depletion of brain glutathione levels in rats: implications for schizophrenia Int. J. Neuropsychopharmacol. 7 2004 262
51. C.C. Wang Reactive oxygen species-induced cell death of rat primary astrocytes through mitochondria-mediated mechanism J. Cell. Biochem. 107 2009 933 943
52. D.M. Otte N-Acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice Neuropsychopharmacology 36 2011 2233 2243
53. S.S. Iyer Oxidation of plasma cysteine/cystine redox state in endotoxin-induced lung injury Am. J. Respir. Cell Mol. Biol. 40 2009 90 98
54. A. Banjac The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death Oncogene 27 2008 1618 1628 (Pubitemid 351347880)
55. R. Vene The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets Antioxid. Redox Signal. 15 2011 2439 2453
56. E.P. Zorrilla Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol. Psychiatry 40 1996 825 833 (Pubitemid 26356716)
57. Y. Dowlati A meta-analysis of cytokines in major depression Biol. Psychiatry 67 2010 446 457
58. M.B. Howren Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis Psychosom. Med. 71 2009 171 186
59. K.D. Denicoff The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells Ann. Intern. Med. 107 1987 293 300 (Pubitemid 17136929)
60. L. Capuron Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions Neuropsychopharmacology 26 2002 643 652 (Pubitemid 34260983)
61. L. Capuron Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon α-2b therapy J. Clin. Oncol. 18 2000 2143 2151 (Pubitemid 30324368)
62. M. Maes The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression Metab. Brain Dis. 24 2009 27 53
63. A.H. Miller Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression Biol. Psychiatry 65 2009 732 741
64. M.M. Nascimento Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study Perit. Dial. Int. 30 2010 336 342
65. K.M. Mahmoud, and A.S. Ammar Effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: a randomized controlled trial Acta Anaesthesiol. Scand. 55 2011 1015 1021
66. C. Csontos Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn Burns 38 2012 428 437
67. G. Chen Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine Mediators Inflamm. 2008 2008 716458
68. M. Khan Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke J. Neurosci. Res. 76 2004 519 527 (Pubitemid 38580467)
69. A.W. Corona Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice Brain Behav. Immun. 2012 10.1016/j.bbi.2012.08.008
70. R. Beloosesky Maternal N-acetyl-cysteine (NAC) protects the rat fetal brain from inflammatory cytokine responses to lipopolysaccharide (LPS) J. Matern. Fetal Neonatal. Med. 25 2012 1324 1328
71. X. Wang N-Acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury Ann. Neurol. 61 2007 263 271 (Pubitemid 46557350)
72. M. Masu Molecular characterisation of NMDA and metabotropic glutamate receptors Ann. N. Y. Acad. Sci. 707 1993 153 164 (Pubitemid 24099475)
73. G. Rajkowska, and J.J. Miguel-Hidalgo Gliogenesis and glial pathology in depression CNS Neurol. Disord. Drug Targets 6 2007 219 233 (Pubitemid 46916253)
74. G.Y. Tsai Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats Clin. Exp. Ophthalmol. 37 2009 223 231
75. K.A. Kigerl System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo Exp. Neurol. 233 2012 333 341
76. P.W. Kalivas Glutamate transmission in addiction Neuropharmacology 56 Suppl. 1 2009 169 173
77. R. Karler Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801 Life Sci. 45 1989 599 606 (Pubitemid 19198546)
78. L. Schmaal N-Acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study Neuropsychopharmacology 37 2012 2143 2152
79. H. Chen Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine Psychopharmacology 222 2012 37 45
80. M. Alvaro-Bartolome Molecular adaptations of apoptotic pathways and signaling partners in the cerebral cortex of human cocaine addicts and cocaine-treated rats Neuroscience 196 2011 1 15
81. T. Watanabe A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine J. Toxicol. Sci. 28 2003 455 469 (Pubitemid 38133224)
82. O.S. El-Tawil d-Amphetamine-induced cytotoxicity and oxidative stress in isolated rat hepatocytes Pathophysiology 18 2011 279 285
83. M. Muriach Cocaine causes memory and learning impairments in rats: involvement of nuclear factor κB and oxidative stress, and prevention by topiramate J. Neurochem. 114 2010 675 684
84. L.A. Knackstedt The role of cysteine-glutamate exchange in nicotine dependence in rats and humans Biol. Psychiatry 65 2009 841 845
85. J.E. Grant A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence Eur. Neuropsychopharmacol. 20 2010 823 828
86. K.M. Gray N-Acetylcysteine (NAC) in young marijuana users: an open-label pilot study Am. J. Addict. 19 2010 187 189
87. K.M. Gray A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents Am. J. Psychiatry 169 2012 805 812
88. F.J. Van Schooten Effects of oral administration of N-acetyl-l-cysteine: a multi-biomarker study in smokers Cancer Epidemiol. Biomarkers Prev. 11 2002 167 175 (Pubitemid 34202998)
89. S.D. Larowe Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals Am. J. Addict. 15 2006 105 110
90. S.D. LaRowe Is cocaine desire reduced by N-acetylcysteine? Am. J. Psychiatry 164 2007 1115 1117 (Pubitemid 47121401)
91. P.N. Mardikian An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 389 394 (Pubitemid 46209420)
92. J.E. Grant N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study Biol. Psychiatry 62 2007 652 657 (Pubitemid 47314380)
93. E.D. Huey A psychological and neuroanatomical model of obsessive-compulsive disorder J. Neuropsychiatry Clin. Neurosci. 20 2008 390 408
94. G.F. Koob, and N.D. Volkow Neurocircuitry of addiction Neuropsychopharmacology 35 2010 217 238
95. E. Ozdemir Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 62 65
96. S. Ersan Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 1039 1042 (Pubitemid 43928217)
97. D.A. Camfield Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 887 895
98. D.L. Lafleur N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder Psychopharmacology 184 2006 254 256 (Pubitemid 43084809)
99. B. Dell'Osso Epidemiologic and clinical updates on impulse control disorders: a critical review Eur. Arch. Psychiatry Clin. Neurosci. 256 2006 464 475 (Pubitemid 46020521)
100. J.E. Grant Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome Harv. Rev. Psychiatry 15 2007 80 85 (Pubitemid 46514891)
101. B.L. Odlaug, and J.E. Grant N-Acetyl cysteine in the treatment of grooming disorders J. Clin. Psychopharmacol. 27 2007 227 229 (Pubitemid 46594953)
102. J.E. Grant N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study Arch. Gen. Psychiatry 66 2009 756 763
103. M. Berk Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting CNS Spectr. 14 2009 357 360
104. G.J. Marek Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol. Pharmacol. 77 2010 317 326
105. O.M. Dean A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice Curr. Med. Chem. 16 2009 2965 2976
106. M. Berk N-Acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial Biol. Psychiatry 64 2008 361 368
107. M. Berk Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia J. Clin. Psychiatry 72 2011 909 913
108. M. Bulut Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia World J. Biol. Psychiatry 10 2009 626 628
109. M. Berk N-Acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial Biol. Psychiatry 64 2008 468 475
110. P.V. Magalhaes N-Acetylcysteine for major depressive episodes in bipolar disorder Rev. Bras. Psiquiatr. 33 2011 374 378
111. P.V. Magalhaes N-Acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial J. Affect. Disord. 129 2011 317 320
112. K.A. Villagonzalo Oxidative pathways as a drug target for the treatment of autism Expert Opin. Ther. Targets 14 2010 1301 1310
113. A.Y. Hardan A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism Biol. Psychiatry 71 2012 956 961
114. M.A. Martinez-Banaclocha N-Acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? Med. Hypotheses 79 1999 8 12
115. J.C. Adair Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease Neurology 57 2001 1515 1517 (Pubitemid 32995744)
116. A. Chan Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension Am. J. Alzheimers Dis. Other Demen. 23 2008 571 585
117. R. Remington Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study Am. J. Alzheimers Dis. Other Demen. 24 2009 27 33
118. L.A. Palmer S-Nitrosothiols signal hypoxia-mimetic vascular pathology J. Clin. Invest. 117 2007 2592 2601 (Pubitemid 47494360)
119. P.U. Devi Facilitation action of N-acetylcysteine on the anticonvulsant effect of sodium valproate in mice Basic Clin. Pharmacol. Toxicol. 98 2006 521 522
120. B. Bailey Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death Ann. Emerg. Med. 44 2004 401 406 (Pubitemid 39237636)
121. M. Berk The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial J. Affect. Disord. 135 2011 389 394